Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kiniksa raises $200mm through Series C

Executive Summary

Kiniksa Pharmaceuticals Ltd. (autoinflammatory and autoimmune disease therapies) raised $200mm in its Series C round. Returning backers Baker Brothers and ArrowMark participated, and were joined by new investors Cormorant, Deerfield, Fidelity Funds, Sofinnova Venture Partners, and Venrock Funds. Entities affiliated with Dr. Robert Desnick also took part, along with company officers and directors.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies